Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 4Phase NA 2Phase 1/2 2Phase 2/3 1Phase 1 1

Status

Completed 29Terminated 8Active not recruiting 4Unknown 3Recruiting 3

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 3Prostate Adenocarcinoma 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × bicalutamide × Clear all
NCT02531516 2026-06-05

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,503 enrolled
Genitourinary

Prostatic Neoplasms

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

NRG Oncology

Phase 3 Active not recruiting
2,753 enrolled
Genitourinary

Prostatic Neoplasms

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT00223145 2025-01-27

PCS III

Université de Sherbrooke

Phase 3 Active not recruiting
600 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡